iZafe Group AB (publ) has signed a letter of intent with Pilloxa AB regarding the acquisition of 100 per cent of the shares in Pilloxa. Pilloxa has developed a technology platform for better compliance that pharmaceutical companies use to design digital patient support. The acquisition creates a new company in digital health that is well positioned to become a leading player in better and safer drug use.
Incorrect or inadequate medication is a significant and costly problem for the individual and drug development companies and costs society substantial sums. Offering patients support to take their medication correctly is an effective way to achieve better medical outcomes. Both iZafe and Pilloxa today offer solutions that support patients in safe medical treatment. The merger means a broader and attractive offer to healthcare providers, the pharmaceutical industry and consumers, broadens the customer base and is expected to contribute to accelerated market penetration through clear sales and margin synergies.
– With Pilloxa’s digital offering and long-term collaboration with the pharmaceutical industry, together with iZafe, we can offer a comprehensive solution for our customers; patients, healthcare professionals and the pharmaceutical industry. Pilloxa’s promise to our customers today is a complete digital solution for patient support within one month of the initiation meeting. We are therefore used to rapid integrations and will immediately begin work on offering a joint digital solution, says Helena Rönnqvist, CEO at Pilloxa.
Pilloxa is a Swedish company that works to develop apps for patients to support them in adherence to their treatment and to connect patients, healthcare providers and the pharmaceutical industry. The company provides a SaaS platform where pharmaceutical companies and other customers can design digital patient support quickly, securely and at a low cost. Connected aids such as Pilloxa’s self-developed smart medication dose can also be connected to the service to support patients in taking the correct medication. Customers and partners include pharmaceutical companies such as Bayer Nordics and the Nordic office of Chiesi Global Rare Diseases, university hospitals such as the University Hospital in Oslo and universities such as the University of Gothenburg.
For more information, please contact:
Press release (in Swedish):